2021年上海市虹口区HIV-1基因亚型及耐药监测结果分析

Analysis on HIV-1 genotype distribution and drug resistance in Hongkou district, Shanghai, 2021

  • 摘要:
    目的  通过监测2021年上海市虹口区HIV-1基因亚型和耐药情况,为虹口区HIV-1耐药数据库的建立和艾滋病防治策略的及时调整提供数据支撑。
    方法  收集2021年1—12月HIV-1感染者血浆样本,使用反转录–巢式PCR技术进行HIV-1病毒Pol基因扩增,通过COMET工具和构建进化树鉴定基因亚型,并采用美国斯坦福大学HIV耐药数据库对其耐药情况进行分析。
    结果  共获得143条Pol基因序列,10种基因亚型,其中CRF01_AE亚型49条(34.27%)、CRF07_BC亚型52条(36.36%)、C亚型13条(9.09%)、B亚型9条(6.29%)、CRF08_BC亚型9条(6.29%)、CRF55_01B亚型4条(2.80%)、CRF67_01B亚型2条(1.40%)、CRF68_01B亚型1条(0.70%)、A亚型1条(0.70%)和独特重组亚型(URFs)3条(2.10%)。 研究发现,治疗前耐药率为10.49%(15/143),其中非核苷类反转录酶抑制剂治疗前耐药率为6.29%(9/143);核苷类反转录酶抑制剂治疗前耐药率为1.40%(2/143);蛋白酶抑制剂治疗前耐药率为2.80%(4/143);利匹韦林、奈韦拉平和依非韦伦治疗前耐药率分别为4.90%、3.50%和3.50%。 此外,监测到传播耐药率为4.20%(6/143),传播耐药突变位点分别为M46I、M184V、K103N、K101E和Y181C,预测对依非韦伦、奈韦拉平、恩曲他滨和拉米夫定为高度耐药。
    结论 HIV-1基因亚型的构成在虹口区已经愈发多样化,应继续加强辖区内HIV-1基因亚型以及耐药毒株的监测工作,特别是非核苷类逆转录酶抑制剂相关的治疗前耐药和传播耐药研究。

     

    Abstract:
    Objective To understand the genotypes and drug resistance of HIV-1 in Hongkou district of Shanghai in 2021, and provide data support for establishing HIV-1 drug resistance database and adjusting prevention and treatment strategies of acquired immune deficiency syndrome in time.
    Methods Plasma samples of HIV-1 positive patients were collected from January to December, 2021, and the Pol gene of HIV-1 was amplified by reverse transcription-nested PCR. The genotypes of HIV-1 were identified by COMET tool and phylogenetic tree, and the drug resistance was analyzed by Stanford University HIV Drug Resistance Database.
    Results A total of 143 Pol sequences and 10 genotypes were obtained. The HIV-1 genotypes included CRF01_ AE, CRF07_ BC, C, B, CRF08_ BC, CRF55_ 01B, CRF67_ 01B, CRF68_ 01B, A, and URFs, accounting for 34.27%, 36.36%, 9.09%, 6.29%, 6.29%, 2.80%, 1.40%, 0.70%, 0.70%, and 2.10%, respectively. It was found that the rate of pretreatment HIV drug resistance (PDR) was 10.49% (15/143). The PDR rate of non-nucleoside reverse transcriptase inhibitors was 6.29% (9/143). The PDR rate of nucleoside reverse transcriptase inhibitors was 1.40% (2/143). The PDR rate of protease inhibitors (PIs) was 2.80% (4/143). The PDR rate of rilpivirine, nevirapine and efavirenz were 4.90%, 3.50% and 3.50%, respectively. In addition, the rate of transmitted HIV drug resistance (TDR) was 4.20% (6/143), and the TDR mutations were detected at M46I, M184V, K103N, K101E and Y181C, which were predicted to be highly resistant to efavirenz, nevirapine, emtricitabine and lamivudine.
    Conclusion The genotypes of HIV-1 in Hongkou are becoming increasingly diverse. Therefore, surveillance for HIV-1 genotypes and drug-resistant strains, especially the PDR and TDR associated with non-nucleoside reverse transcriptase inhibitors, should be further strengthened.

     

/

返回文章
返回